PRCT PROCEPT BioRobotics Corp

Nasdaq procept-biorobotics.com


$ 28.59 $ 0.52 (1.86 %)    

Friday, 21-Nov-2025 10:44:54 EST
QQQ $ 582.81 $ -4.52 (-0.77 %)
DIA $ 459.86 $ 0.39 (0.08 %)
SPY $ 652.56 $ -2.45 (-0.37 %)
TLT $ 89.55 $ -0.11 (-0.12 %)
GLD $ 373.72 $ -0.27 (-0.07 %)
$ 27.89
$ 28.15
$ 28.74 x 1
$ 28.89 x 112
$ 28.15 - $ 28.95
$ 27.84 - $ 100.89
1,568,532
na
1.56B
$ 1.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 td-cowen-maintains-buy-on-procept-biorobotics-lowers-price-target-to-50

TD Cowen analyst Joshua Jennings maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price target from $85...

 piper-sandler-reiterates-overweight-on-procept-biorobotics-lowers-price-target-to-50

Piper Sandler analyst Matt O'Brien reiterates PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price t...

 wells-fargo-maintains-overweight-on-procept-biorobotics-lowers-price-target-to-51

Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price targe...

 procept-biorobotics-sees-fy2026-sales-410000m-430000m-vs-427376m-est

PROCEPT BioRobotics (NASDAQ:PRCT) sees FY2026 sales of $410.000 million-$430.000 million vs $427.376 million analyst estimate.

 procept-biorobotics-affirms-fy2025-sales-guidance-of-325500m-vs-326566m-est

PROCEPT BioRobotics (NASDAQ:PRCT) affirms FY2025 sales outlook from $325.500 million to $325.500 million vs $326.566 million es...

 procept-biorobotics-q3-eps-038-beats-040-estimate-sales-83327m-beat-80943m-estimate

PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $...

 truist-securities-maintains-buy-on-procept-biorobotics-lowers-price-target-to-50

Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and lowers the price targe...

 btig-reiterates-neutral-on-procept-bioroboticsto-neutral

BTIG analyst Ryan Zimmerman reiterates PROCEPT BioRobotics (NASDAQ:PRCT) from Neutral to Neutral.

 oppenheimer-upgrades-procept-biorobotics-to-outperform-announces-60-price-target

Oppenheimer analyst Suraj Kalia upgrades PROCEPT BioRobotics (NASDAQ:PRCT) from Perform to Outperform and announces $60 pric...

 wells-fargo-maintains-overweight-on-procept-biorobotics-lowers-price-target-to-58

Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price targe...

 piper-sandler-maintains-overweight-on-procept-biorobotics-lowers-price-target-to-55

Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price ta...

 procept-biorobotics-raises-fy2025-sales-guidance-from-323000m-to-325500m-vs-324423m-est

PROCEPT BioRobotics (NASDAQ:PRCT) raises FY2025 sales outlook from $323.000 million to $325.500 million vs $324.423 million est...

 procept-biorobotics-q2-eps-035-beats-041-estimate-sales-79182m-beat-75921m-estimate

PROCEPT BioRobotics (NASDAQ:PRCT) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $...

 procept-biorobotics-announces-preliminary-q2-revenue-of-792m

SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) ("the Company"), a surgical robot...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION